Literature DB >> 10373712

Clopidogrel with aspirin is the optimal antiplatelet regimen for intracoronary stenting.

S R Steinhubl1, E J Topol.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10373712     DOI: 10.1023/a:1008981408216

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


× No keyword cloud information.
  17 in total

1.  Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase.

Authors:  D C Mills; R Puri; C J Hu; C Minniti; G Grana; M D Freedman; R F Colman; R W Colman
Journal:  Arterioscler Thromb       Date:  1992-04

2.  Intracoronary stenting and risk for major adverse cardiac events during the first month.

Authors:  H Schühlen; A Kastrati; J Dirschinger; J Hausleiter; S Elezi; A Wehinger; J Pache; M Hadamitzky; A Schömig
Journal:  Circulation       Date:  1998-07-14       Impact factor: 29.690

Review 3.  Subacute stent thrombosis: evolving issues and current concepts.

Authors:  K H Mak; G Belli; S G Ellis; D J Moliterno
Journal:  J Am Coll Cardiol       Date:  1996-02       Impact factor: 24.094

4.  Platelet anti-aggregating activity and tolerance of clopidogrel in atherosclerotic patients.

Authors:  B Boneu; G Destelle
Journal:  Thromb Haemost       Date:  1996-12       Impact factor: 5.249

5.  A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.

Authors: 
Journal:  Lancet       Date:  1996-11-16       Impact factor: 79.321

6.  The duration of pretreatment with ticlopidine prior to stenting is associated with the risk of procedure-related non-Q-wave myocardial infarctions.

Authors:  S R Steinhubl; M S Lauer; D P Mukherjee; D J Moliterno; A M Lincoff; S G Ellis; E J Topol
Journal:  J Am Coll Cardiol       Date:  1998-11       Impact factor: 24.094

7.  A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators.

Authors:  D L Fischman; M B Leon; D S Baim; R A Schatz; M P Savage; I Penn; K Detre; L Veltri; D Ricci; M Nobuyoshi
Journal:  N Engl J Med       Date:  1994-08-25       Impact factor: 91.245

8.  Angiographic follow-up after placement of a self-expanding coronary-artery stent.

Authors:  P W Serruys; B H Strauss; K J Beatt; M E Bertrand; J Puel; A F Rickards; B Meier; J J Goy; P Vogt; L Kappenberger
Journal:  N Engl J Med       Date:  1991-01-03       Impact factor: 91.245

9.  A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents.

Authors:  A Schömig; F J Neumann; A Kastrati; H Schühlen; R Blasini; M Hadamitzky; H Walter; E M Zitzmann-Roth; G Richardt; E Alt; C Schmitt; K Ulm
Journal:  N Engl J Med       Date:  1996-04-25       Impact factor: 91.245

10.  Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.

Authors: 
Journal:  Lancet       Date:  1998-07-11       Impact factor: 79.321

View more
  4 in total

Review 1.  Changing roles of anticoagulant and antiplatelet treatment during percutaneous coronary intervention.

Authors:  R V Kelly; S Steinhubl
Journal:  Heart       Date:  2005-06       Impact factor: 5.994

Review 2.  Clopidogrel: a review of its use in the prevention of atherothrombosis.

Authors:  B Jarvis; K Simpson
Journal:  Drugs       Date:  2000-08       Impact factor: 9.546

Review 3.  Optimizing antiplatelet therapy in coronary interventions.

Authors:  S B King
Journal:  Clin Cardiol       Date:  2000-11       Impact factor: 2.882

Review 4.  Antiplatelet therapy in secondary stroke prevention.

Authors:  B B Worrall; K C Johnston
Journal:  Curr Atheroscler Rep       Date:  2000-03       Impact factor: 5.967

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.